A Phase 2, Open-Label, Study Evaluating Safety and Efficacy of the Loncastuximab in Relapsed/Refractory Marginal Zone Lymphoma

Disease Sites:

Lymphoma

Staging:

Phase II

Age Group:

Adults

Therapies:

Mol. targeted/Immunotherapy/Biologics

Drugs:

Loncastuximab Tesirine

Principal Investigator(s):

Oluwole, Olalekan

Scope:

National

Participating Institutions:

Vanderbilt University

Open Date:

06-12-2025

Trial Type:

Treatment

Protocol ID:

VICC-ITCTT23024

National Clinical Trial ID:

NCT05296070

Eligibility

Ages Eligible for Study:

Not Available

Genders Eligible for Study:

Not Available

Accepts Healthy Volunteers?:

Not Available